

Article

# Design and Synthesis of Pyrrolidinyl Ferrocene-Containing Ligands and Their Application in Highly Enantioselective Rhodium-Catalyzed Olefin Hydrogenation

 Xin Li <sup>1</sup>, Therese B. Brennan <sup>2</sup>, Cian Kingston <sup>1,3</sup>, Yannick Ortin <sup>1</sup> and Patrick J. Guiry <sup>1,3,\*</sup>,<sup>†</sup>
<sup>1</sup> Centre for Synthesis and Chemical Biology, School of Chemistry, University College Dublin, Belfield, D04 N2E5 Dublin, Ireland

<sup>2</sup> MSD Ballydine, Kilsheelan, Co. Tipperary, E91 V091 Clonmel, Ireland

<sup>3</sup> Synthesis and Solid State Pharmaceutical Centre, School of Chemistry, University College Dublin, Belfield, D04 N2E5 Dublin, Ireland

\* Correspondence: p.guiry@ucd.ie; Tel.: +353-1-716-2309

<sup>†</sup> Dedicated with respect and admiration to Professor Henri Kagan, a pioneer in asymmetric catalysis.

**Abstract:** Herein, we report the design and synthesis of a series of chiral pyrrolidine-substituted ferrocene-derived ligands. The proficiency of this novel structural motif was demonstrated in the Rh-catalyzed asymmetric hydrogenation of dehydroamino acid esters and  $\alpha$ -aryl enamides. The products were obtained with full conversions and excellent levels of enantioselectivities of up to >99.9% ee and 97.7% ee, respectively, using a BINOL-substituted phosphine-phosphoramidite ligand which possesses planar, central, and axial chirality elements.

**Keywords:** chiral ligand; ferrocene; asymmetric catalysis; rhodium-catalyzed olefin reduction



**Citation:** Li, X.; Brennan, T.B.; Kingston, C.; Ortin, Y.; Guiry, P.J. Design and Synthesis of Pyrrolidinyl Ferrocene-Containing Ligands and Their Application in Highly Enantioselective Rhodium-Catalyzed Olefin Hydrogenation. *Molecules* **2022**, *27*, 6078. <https://doi.org/10.3390/molecules27186078>

Academic Editor: Victor Mamane

Received: 13 August 2022

Accepted: 13 September 2022

Published: 17 September 2022


**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction


Phosphorous-based ligands have found extensive use in homogeneous transition metal catalysis [1–3]. Bidentate P,P based structures, exemplified by BINAP, DuPhos and Josiphos, represent a privileged ligand scaffold in transition-metal catalysis (Figure 1) [4]. Ferrocenyl-based Josiphos derivatives have proven to be efficient ligands across a range of enantioselective processes, particularly in the field of olefin hydrogenations [5,6]. Their value has been demonstrated in the large-scale Ir-catalyzed hydrogenation of an N-aryl imine in the synthesis of the herbicide (S)-metolachlor [7]. Thus, the increasing demand for efficient enantioselective technologies has led to significant investigation of ligand derivatives, as evidenced by the range of commercially available variants and sub-families such as Knochel's Ferriphos ligands [8].



**Figure 1.** Examples of privileged P,P ligands.

Focusing on planar chiral ferrocene compounds and their ease of preparation through the use of diastereoselective *ortho*-metalating groups, including amines, sulfoxides, acetals, oxazolines, azepines, sulfoximines, and hydrazones, has contributed to the wide range of planar chiral ferrocene ligands reported to date [9]. We reported the preparation of ferrocenylphosphinamine ligands of type 1, Figure 2, possessing both planar and


central chirality obtained through diastereoselective metalation of *trans*-(2*R*,5*R*)-2,5-dialkyl-1-(ferrocenylmethyl)pyrrolidines and their application in Pd-catalysed allylic alkylation [10].



**Figure 2.** Selected ferrocene-pyrrolidine containing ligands.

Thus, interested by the successful application of ferrocene-containing ligands, bearing an  $\alpha$ -chiral center, and extending our work on pyrrolidine-containing P,N ligands [11–13], we developed novel ferrocene ligands in which the  $\alpha$ -chiral center is incorporated into a pyrrolidine unit. We had previously reported the enantioselective preparation of ferrocenepyrrolidine (*R*)-**2** and applied it in the diastereoselective formation of a series of N,O ligands of type **3** for the diethylzinc-mediated addition to aldehydes, affording enantioselectivities of up to 95% ee [14]. In addition, we reported the synthesis of novel ferrocene-phosphinamine ligands of type **4**, again obtained through diastereoselective *ortho*-metalation of ferrocenepyrrolidine (*R*)-**2**, Figure 2, and their application in the Pd-catalyzed allylic alkylation of 1,3-diphenylprop-2-enyl acetate with dimethyl malonate gave enantioselectivities of up to 77% ee [15].

In 2002, Boaz reported the synthesis of air-stable ‘BoPhoz’ ferrocenylphosphine-aminophosphine ligands (**5**, Figure 3), which were highly effective in the asymmetric hydrogenation of dehydro- $\alpha$ -amino acids, itaconic acids, and  $\alpha$ -ketoesters [16,17]. Two different phosphorus donor atoms generate electronic asymmetry at the metal centre which then provides unique modulation of the catalyst activity. Derivatization of the ligands led to an expansion of the range of suitable substrates for hydrogenation [18–20] and identified the proficiency of the ligands in the catalytic asymmetric synthesis of cyclohexenone-based atropisomers [21]. Chang and Zheng introduced a phosphine-phosphoramidite scaffold (**6**, Figure 3) which proved effective in the asymmetric hydrogenation of a broad range of substrates including both (*Z*)- and (*E*)-aryl and  $\beta$ -alkyl- $\beta$ -(acylamino)acrylates [22–24]. With the success of the reported ligand derivatizations in mind, it occurred to us that the flexible amino sidechain in **5** and **6** could be modified to introduce the more rigid pyrrolidinyl motif found in **3** and **4**. Herein, we present the preparation of a variety of ferrocenylphosphine-aminophosphine and ferrocenylphosphine-phosphoramidite ligands of type **7** and **8**. The relatively facile introduction of the amino-phosphine moiety introduces a modular element, which enabled the preparation of a diverse range of novel ligands for investigation.




**Figure 3.** Ferrocenylphosphine-aminophosphine and ferrocenylphosphine-phosphoramidite ligands.

## 2. Results and Discussion

### 2.1. Synthesis and Characterization of N-Phosphorus-Substituted Pyrrolidine Based Ligands


The strategy for the preparation of ferrocenyl N-phosphinepyrrolidinyl ligands was adapted from our previous work on the ferrocene-phosphinamine ligands of type **4** [15].

The synthesis of pyrrolidine (*R*)-**13** from ferrocene (**9**), consisted of a Friedel-Crafts acylation to afford ketone (**10**), a Corey-Bakshi-Shibata oxazaborolidine-mediated enantioselective reduction to afford alcohol (*R*)-**11**, its acetylation to afford acetate (*R*)-**12** and finally treatment with allylamine to give (*R*)-**13** in a 92% yield over four steps (Scheme 1).




**Scheme 1.** Enantioselective synthesis of (*R*)-**13**.

The introduction of the ferrocenyl phosphine moiety was accomplished by non-selective *ortho*-lithiation of (*R*)-**13**, which was then quenched with chlorodiphenylphosphine (Scheme 2). Diastereomers (*R,S*)-**14** and (*R,R*)-**14** were separated by silica gel column chromatography and isolated in yields of 24% and 33%, respectively. To facilitate the introduction of the *N*-pyrrolidinyl phosphine substituent, deallylation of the amine was accomplished using palladium(tetrakis(triphenylphosphine)) and *N,N*-dimethyl barbituric acid (NDMBA) [25]. Deprotected pyrrolidines (*R,S*)-**15** and (*R,R*)-**15** were isolated in yields of 98% and 86%, respectively. With the synthetic precursors to the desired ligands in hand, the final coupling could now be performed using triethylamine and the appropriate chlorodiarylphosphine. The initial series of ligands **L1–6** were synthesized using (*R,S*)-**15**. Ligands bearing neutral (**L1**), electron rich (**L2**), and electron poor (**L3–L4**) aryl groups were synthesized in moderate to good yields (40–78%). The proficiency of a BINOL unit in ferrocenyl bisphosphonate [26], phosphoramidite [27,28], and phosphine-phosphoramidite ligands [24] for enantioselective rhodium-catalyzed hydrogenation has been well-documented. Therefore, phosphoramidites **L5** and **L6** were synthesized using (*R*)- or (*S*)-1,1'-binaphthyl-2,2'-diyl phosphorochloridate in good yields of 83 and 70%, respectively. In order to test the effect of a switch in planar chirality, isomeric ligands **L7** and **L8** were synthesized from (*R,R*)-**15** in excellent yields of 90% and 98%, respectively (Figure 4).




**Scheme 2.** Enantioselective synthesis of **L1–L8**.



**Figure 4.** Series of novel ligands L1–L8 prepared.

Interestingly,  $^5J$  coupling between the phosphorus atoms was observed for ligands L1–L6 with coupling constants ranging from 16.4 to 56.2 Hz. Cross peaks in the two-dimensional  $^{31}\text{P}\{^1\text{H}\}$ – $^{31}\text{P}\{^1\text{H}\}$  spectra ( $^{31}\text{P}$  COSY) provided further evidence for this unexpected interaction (Figure 5). Although ‘long range couplings’ (across more than four bonds) between two phosphorus atoms are quite rare, the phenomenon has been observed with several ligands, such as Xantphos ( $^6J$  coupling) and tetraphosphine ferrocenyl derivatives [29]. An excellent in-depth study of the ferrocenyl compounds attributed the  $^{31}\text{P}$ – $^{31}\text{P}$  nuclear spin-spin coupling to a through-space non-bonded interaction of the phosphorus lone pairs, as was previously observed in  $^{19}\text{F}$ – $^{19}\text{F}$  and  $^{15}\text{N}$ – $^{19}\text{F}$  couplings [30]. Due to the magnitude of the coupling constants observed for L1–L6, it is unlikely a through-bond interaction ( $\sigma$ - and  $\pi$ -transmitted components) is taking place. Through-space coupling results from overlap of the phosphorus lone-pair orbitals. Although the interaction provides an adequate pathway to transmit spin information between the nuclei, it does not lead to chemical bonding because both orbitals are occupied.



**Figure 5.** Two-dimensional  $^{31}\text{P}\{^1\text{H}\}$ – $^{31}\text{P}\{^1\text{H}\}$  spectra ( $^{31}\text{P}$  COSY) of L1.


A comparison of the  $J_{\text{PP}}$  coupling constants in L1–L8 revealed a considerable effect resulting from the choice of aryl phosphine-substitution (Table 1). The magnitude of the coupling constant depends on the extent of the lone-pair overlap, providing some information on the P–P orientation and proximity in solution. No coupling was observed for L7–L8 indicating the planar and central chirality of the ligand prohibit favorable alignment

of the lone pairs. These factors could provide useful information on the bite angle and play an important role in the future development and application of this class of ligand.

**Table 1.** Magnitude of the  $^{ts}J_{PP}$  coupling constants in L1–L8.

Ligand	$^{ts}J_{PP}$ (Hz)
L1	16.4
L2	26.0
L3	19.5
L4	26.2
L5	56.2
L6	29.3
L7	-
L8	-

X-ray crystallographic analysis of L5 provided confirmation of the assignment of the planar, central, and axial chirality in the molecule; 15% oxidation of the ferrocenyl phosphorous atom (P1) was observed (Figure 6). The distance between the phosphorus atoms was measured at 3.9 Å, which favorably compared to Meunier’s observation of coupling constants over 20 Hz with P–P distances of 4.0 Å or below [30]. However, the solid-state conformation of L5 obtained from X-ray structural data should not reflect the conformation in solution due to effects of crystal-packing, meaning the true inter-phosphorus distance remains unknown.



**Figure 6.** X-ray crystallographic analysis of L5 (15 % oxidation of P1 was observed).

### 2.1.1. Rhodium-Catalyzed Asymmetric Hydrogenation of Dehydroamino Acid Esters


Transition metal-catalyzed asymmetric hydrogenation of dehydroamino acid derivatives is a valuable method for the preparation of amino acid precursors [31]. As such, the field has undergone extensive investigation since the 1970s, from the seminal work of Knowles and Kagan [32–34], thereby providing a convenient test reaction to test the efficiency of the rhodium complexes of our novel ligands L1–L8.

#### Reaction Condition Optimization

(Z)-Methyl-2-acetamido-3-phenylacrylate **16a** was chosen as a suitable substrate to test the application of ligands L1–L8 (Table 2). Initial conditions consisted of Rh(COD)<sub>2</sub>OTf as the rhodium source, with ligand L1 in THF at room temperature under an atmosphere of hydrogen for 12 h. Full conversion of the starting material was observed with an ee of 89.0 % ee for the product (Table 2, entry 2). When Rh(COD)<sub>2</sub>BF<sub>4</sub> was employed a drop in the conversion of starting material was observed, although the product was formed in a similar ee (Table 2, entry 3). This effect was subsequently observed throughout the optimization process (Table 2, entries 11, 18). Increasing the hydrogen pressure was found to have a detrimental effect upon the ee of the product (Table 2, entries 4–5). Similarly, variation of the solvent had a deleterious effect upon the ee and in some cases, the conversion (Table 2, entries 6–10). Poor asymmetric induction and conversion were observed upon switching to ligand L2, which bears an *o*-tolyl substituted phosphine (Table 2, entries 12–13). The comparatively electron-poor *p*-fluoro substituted L3 gave a similar result to that obtained previously with ligand L1 (Table 2, entry 14). Switching to 3,5-di(trifluoromethyl)-substituted ligand L4, the product was formed in 92.2% ee with full conversion after 2 h, and the ee was further increased to 95.5% upon cooling the reaction mixture to 0 °C for 3 h (Table 2, entries 15–16). An (*R*)-BINOL-based system was next evaluated in

the application of ligand **L5**. Gratifyingly, full conversion of **16a** was found in 12 h, with the product formed in an excellent enantiomeric excess of 97.9% (Table 2, entry 18). In this case, upon repetition with Rh(COD)<sub>2</sub>BF<sub>4</sub>, no decrease in the conversion of the starting material was observed (Table 2, entry 19). By increasing the hydrogen pressure to 10 bar, full conversion of the starting material was observed within 2 h, but the ee of the product dropped slightly (Table 2, entry 20). Variation of the solvent did not have a beneficial effect upon the enantioselectivity of the reaction (Table 2, entries 21–22). Interestingly, changing the axial chirality using (*S*)-BINOL in ligand **L6** resulted in a significantly lower ee for the product (Table 2, entry 23). The best result was obtained by switching the planar chirality, as illustrated in ligand **L7**, where full conversion of the starting material was observed in one hour and an ee of 99.5% was obtained (Table 2, entry 24). By increasing the hydrogen pressure to 20 bar and the reaction time to 4 h, the catalyst loading could be significantly lowered to only 0.02 mol %, with minimal effect on the enantioselectivity of product formation (Table 2, entry 25). Interestingly, in contrast to the planar isomers (ligand **L5** and **L6**), when the opposite hand of BINOL was used with ligand **L8**, the opposite enantiomer of the product was formed, albeit with a much lower ee of 46.7% (Table 2, entry 26). For comparison purposes, the results obtained in the literature using rhodium complexes of Josiphos, DuPhos, and BoPhoz ligands are included (Table 1, entries 27–29). Our optimal ligand (99.5% ee) compares favorably with DuPhos (85% ee) and Josiphos (96% ee) and is identical to the level of enantioselectivity exhibited by the BoPhoz ligand (99.5% ee).

**Table 2.** Screening of asymmetric hydrogenation conditions with substrate **16a**.




Entry	Ligand	Rh Source	Solvent	H <sub>2</sub> Pressure (bar)	Time (h)	Conv. (%) <sup>[a]</sup>	Ee (%) <sup>[b]</sup>
1	(±)-BINAP	Rh(COD) <sub>2</sub> OTf	THF	2.3	15	>99	-
2	<b>L1</b>	Rh(COD) <sub>2</sub> OTf	THF	1	12	>99	89.0
3	<b>L1</b>	Rh(COD) <sub>2</sub> BF <sub>4</sub>	THF	1	12	78.7	90.0
4	<b>L1</b>	Rh(COD) <sub>2</sub> OTf	THF	20	2	>99	76.3
5	<b>L1</b>	Rh(COD) <sub>2</sub> OTf	THF	40	1	>99	71.2
6	<b>L1</b>	Rh(COD) <sub>2</sub> OTf	DCM	1	12	>99	85.3
7	<b>L1</b>	Rh(COD) <sub>2</sub> OTf	MeOH	1	12	>99	85.7
8	<b>L1</b>	Rh(COD) <sub>2</sub> OTf	DMF	1	12	42.5	80.2
9	<b>L1</b>	Rh(COD) <sub>2</sub> OTf	1,4-Dioxane	1	12	66	82.8
10	<b>L1</b>	Rh(COD) <sub>2</sub> OTf	Toluene	1	12	50	80.3
11	<b>L1</b>	Rh(COD) <sub>2</sub> BF <sub>4</sub>	Toluene	1	12	38.3	81.8
12	<b>L2</b>	Rh(COD) <sub>2</sub> OTf	THF	1	12	70.6	27.3
13	<b>L2</b>	Rh(COD) <sub>2</sub> OTf	DCM	1	10	64.3	17.6
14	<b>L3</b>	Rh(COD) <sub>2</sub> OTf	THF	1	12	>99	88.9
15	<b>L4</b>	Rh(COD) <sub>2</sub> OTf	THF	1	2	>99	92.2
16 <sup>[c]</sup>	<b>L4</b>	Rh(COD) <sub>2</sub> OTf	THF	1	3	>99	95.5
17 <sup>[c]</sup>	<b>L4</b>	Rh(COD) <sub>2</sub> BF <sub>4</sub>	THF	1	4	97	95.4
18	<b>L5</b>	Rh(COD) <sub>2</sub> OTf	THF	1	12	>99	97.9
19	<b>L5</b>	Rh(COD) <sub>2</sub> BF <sub>4</sub>	THF	1	12	>99	97.7
20	<b>L5</b>	Rh(COD) <sub>2</sub> OTf	THF	10	2	>99	95.3
21	<b>L5</b>	Rh(COD) <sub>2</sub> OTf	DCM	1	12	>99	97.7
22	<b>L5</b>	Rh(COD) <sub>2</sub> OTf	MeOH	1	12	>99	92.3
23	<b>L6</b>	Rh(COD) <sub>2</sub> OTf	THF	1	12	>99	86.7
24	<b>L7</b>	Rh(COD) <sub>2</sub> OTf	THF	1	1	>99	99.5
25 <sup>[d]</sup>	<b>L7</b>	Rh(COD) <sub>2</sub> OTf	THF	20	4	>99	97.7
26	<b>L8</b>	Rh(COD) <sub>2</sub> OTf	THF	1	12	>99	46.7 ( <i>R</i> )
27 <sup>[5]</sup>	( <i>R,S</i> )-Josiphos	Rh(COD) <sub>2</sub> OTf	MeOH	1	0.33	>99	96
28 <sup>[35]</sup>	DuPhos	Rh(COD) <sub>2</sub> OTf	MeOH	2 (atm)	1	>99	85
29 <sup>[16]</sup>	BoPhoz	Rh(COD) <sub>2</sub> OTf	THF	1	1	96	99.5

Reactions were performed on a 0.5-mmol **16a** scale; see the Supporting Information for further details. <sup>[a]</sup> Determined by <sup>1</sup>H NMR spectroscopy of the crude product. <sup>[b]</sup> Determined by high performance liquid chromatography using a chiral stationary phase. <sup>[c]</sup> Reaction performed at 0 °C. <sup>[d]</sup> 0.02 mol % Rh(COD)<sub>2</sub>OTf and 0.022 mol % ligand used, reaction performed on 2.5 mmol **16a** scale.

### Substrate Scope

With optimum conditions in hand, the activity of a selection of ligands was investigated with a variety of amino acid precursors (Scheme 3). As the best ligand from the optimization process, **L7** consistently gave excellent results of full conversion and over 99% ee regardless of any electron-rich (**16b**, **16c**, **16j**) or electron-poor substituents (**16d–16i**) on the  $\beta$ -aryl moiety or the particular substitution pattern of the substrate. The excellent performance also extended to a dehydroamino acid ester without aryl substitution (**16k**). Phenyl-substituted ligand **L1** was also tested across a selection of the substrates and gave consistent levels of asymmetric induction (88.5–92.0% ee) but variable conversions of the starting material from (60–>99%). The rhodium complex of ligand **L4** bearing 3,5-di(trifluoromethyl)phenyl substituents also led to product formation, with full conversions and remarkably consistent, although lower, enantioselectivities regardless of the starting material (92.5–96.3% ee).



**Scheme 3.** Substrate scope of dehydroamino acid esters **16a–k**. Reactions with **L1** (1.1 mol %) were performed using Rh(COD)<sub>2</sub>OTf (1.0 mol %), 1 bar H<sub>2</sub>, in THF for 12 h at room temperature. Reactions with **L4** (1.1 mol %) were performed using Rh(COD)<sub>2</sub>OTf (1.0 mol %), 1 bar H<sub>2</sub>, in THF for 4 h at 0 °C. Reactions with **L7** (0.22 mol %) were performed using Rh(COD)<sub>2</sub>OTf (0.2 mol %), 10 bar H<sub>2</sub>, in THF for 12 h at room temperature. See the Supporting Information for further details.

#### 2.1.2. Rhodium-Catalyzed Asymmetric Hydrogenation of $\alpha$ -Aryl Enamides

With the success of the rhodium complexes in the highly enantioselective reduction of dehydroamino acids, the efficiency of the ligands was next tested in the rhodium-catalyzed hydrogenation of a selection of  $\alpha$ -aryl enamides. This is a valuable process for the construction of a variety of amines.

#### Reaction Condition Optimization

*N*-(1-phenylvinyl)acetamide **18a** was chosen as the model substrate for optimization studies. Ligand **L1** was tested using Rh(COD)<sub>2</sub>OTf in THF at room temperature with 40 bar hydrogen pressure for 2 h. While full conversion of the starting material was observed, a disappointing ee for the product of 33.6% (*S*) was observed (Table 3, entry 2). Decreasing the hydrogen pressure did not have a significant effect on the level of asymmetric induction (Table 3, entry 3). Shortening the reaction time to 1 h and switching to MeOH as solvent provided a slight increase to 46.0% ee (Table 3, entry 5). While ligands

**L2** and **L3** were similarly ineffective, a dramatic improvement was observed upon using the 3,5-di(trifluoromethyl)-substituted ligand **L4** with an ee of 91.3% (Table 3, entries 6–8).

**Table 3.** Screening of asymmetric hydrogenation conditions with substrate **18a**.

Entry	Ligand	Solvent	H <sub>2</sub> Pressure (bar)	Time (h)	Conv. (%) <sup>[a]</sup>	Ee (%) <sup>[b]</sup>
1	(±)-BINAP	THF	40	18	>99	-
2	<b>L1</b>	THF	40	2	>99	33.6
3	<b>L1</b>	THF	20	2	>99	33.4
4	<b>L1</b>	CH <sub>2</sub> Cl <sub>2</sub>	20	2	>99	29.5
5	<b>L1</b>	MeOH	20	1	>99	46.0
6	<b>L2</b>	MeOH	20	1	>99	12.5
7	<b>L3</b>	MeOH	20	1	>99	45.6
8	<b>L4</b>	MeOH	20	1	>99	91.3
9	<b>L5</b>	THF	10	2	>99	92.0
10	<b>L5</b>	THF	1	3	42	89.2
11	<b>L7</b>	THF	1	2.5	>99	96.4
12	<b>L7</b>	THF	10	1	>99	96.0
13 <sup>[c]</sup>	<b>L7</b>	THF	10	1	>99	91.0
14	<b>L8</b>	THF	1	2	59	31.7 (R)
15 <sup>[36]</sup>	Me-BPE	MeOH	4 (atm)	12	>99	95.2
16 <sup>[22]</sup>	BoPhoz	CH <sub>2</sub> Cl <sub>2</sub>	10	1	99.5	61.8

Reactions were performed on a 0.5 mmol **18a** scale, see the Supporting Information for further details. <sup>[a]</sup> Determined by <sup>1</sup>H NMR spectroscopy of the crude product. <sup>[b]</sup> Determined by high performance liquid chromatography using a chiral stationary phase. <sup>[c]</sup> 0.2 mol % Rh(COD)<sub>2</sub>OTf, 0.21 mol % ligand used.


Switching to ligand **L5** in THF at 10 bar hydrogen provided the product with similar levels of asymmetric induction (Table 3, entry 9). Decreasing the pressure further to 1 bar resulted in decreased conversion of the starting material (Table 3, entry 10). As in our previous optimization, the best result was observed with ligand **L7**, with an ee of 96.4% observed and full conversion after 2.5 h (Table 3, entry 11). A similar ee was observed with 10 bar hydrogen pressure after 1 h while decreasing the catalyst loading to 0.2 mol % provided the product in 91.0 % ee (Table 3, entries 12–13). Once again, switching the axial chirality of the BINOL moiety provided the opposite enantiomeric product in a much-lowered ee of 31.7 % (Table 3, entry 14). For comparison purposes, the results obtained in the literature using rhodium complexes of Me-BPE (related to DuPhos) and BoPhoz ligands are included (Table 2, entries 15–16). Our optimal ligand (96.4% ee) compares closely with Me-BPE (95.2% ee) but outperforms the level of enantioselectivity exhibited by the BoPhoz ligand (61.8% ee).

### Substrate Scope

The optimized conditions with ligand **L7** were tested across a range of α-aryl enamides (**18a–f**) and, in contrast to the investigation of dehydroamino acids, the results were substrate-dependent (Scheme 4). Naphthyl (**18b**) and 4-chloro (**18c**) substitution of the aryl ring resulted in full conversions and excellent enantioselectivities (97.4–97.7% ee), but a lower ee of 93.7% was observed with a 4-methoxy substituent (**18d**). Ligand **L4** was also tested in the synthesis of **19b** and **19c** and the products were formed in slightly lower enantioselectivities (92.0–92.4% ee), while a significant drop in the level of asymmetric induction was seen for the formation of **19d** (77.6% ee). Poor conversion of the starting material and low level of asymmetric induction were observed in the hydrogenation of bicyclic *N*-(3,4-dihydro-1-naphthyl)acetamide **18e** with ligand **L7** (23% conversion, 48.0% ee) and ligand **L4** (12% conversion, 27.0% ee). A similarly poor result was observed in the hydrogenation of β-phenyl-β-(acylamino)acrylate **18f** with ligand **L7** (18% conversion,



15.3% ee). However, a drastic improvement to full conversion to the product with an ee of 61.3% was observed with ligand **L1**. The result demonstrates the need for substrate dependent optimization with a new class of substrate to maximize the potential of the ligand series developed.



**Scheme 4.** Substrate scope of  $\alpha$ aryl enamides **18a–f**. Reactions with **L1** (1.1 mol %) were performed using Rh(COD)<sub>2</sub>OTf (1.0 mol %), 40 bar H<sub>2</sub>, in CH<sub>2</sub>Cl<sub>2</sub> for 24 h at room temperature. Reactions with **L4** (1.1 mol %) were performed using Rh(COD)<sub>2</sub>OTf (1.0 mol %), 20 bar H<sub>2</sub>, in MeOH for 1 h at room temperature. Reactions with **L7** (0.22 mol %) were performed using Rh(COD)<sub>2</sub>OTf (0.2 mol %), 10 bar H<sub>2</sub>, in THF for 1 h at room temperature except for substrate **18f**, which was subjected to Rh(COD)<sub>2</sub>OTf (1.0 mol %), **L7** (1.1 mol %), 60 bar H<sub>2</sub>, in THF for 2 h at room temperature. See the Supporting Information for further details.

### 3. Materials and Methods—Chemistry

Unless otherwise noted, reactions were performed with rigorous exclusion of air and moisture under an inert atmosphere of nitrogen in flame-dried glassware with magnetic stirring using anhydrous solvents. N<sub>2</sub>-flushed stainless steel cannulas or plastic syringes were used to transfer air and moisture-sensitive reagents. All reagents were obtained from commercial sources and used without further purification unless otherwise stated. All anhydrous solvents were obtained from commercial sources (Sigma Aldrich, Glasgow, United Kingdom) and used as received with the following exceptions: diethyl ether (Et<sub>2</sub>O), dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>), and toluene (PhCH<sub>3</sub>) were dried by passing through activated alumina columns. Powdered activated 4 Å molecular sieves were purchased from Sigma Aldrich (Glasgow, United Kingdom) and were stored in an oven at 120 °C. In vacuo refers to the evaporation of solvent under reduced pressure on a rotary evaporator. Thin-layer chromatography (TLC) was performed on aluminium plates pre-coated with silica gel F254 (Merck, Darmstadt, Germany). They were visualised with UV-light (254 nm) fluorescence quenching, or by charring with Hanessian's staining solution (cerium molybdate, H<sub>2</sub>SO<sub>4</sub> in water), basic potassium permanganate staining solution (potassium permanganate, K<sub>2</sub>CO<sub>3</sub> and NaOH in water), or an acidic vanillin staining solution (vanillin, H<sub>2</sub>SO<sub>4</sub> in ethanol). Flash column chromatography was carried out using 40–63  $\mu$ m, 230–400 mesh silica gel.

<sup>1</sup>H NMR spectra were recorded on a 300-, 400-, or 500-MHz spectrometer. <sup>13</sup>C NMR spectra were recorded on a 400- or 500-MHz spectrometer (Agilent, Birmingham, United Kingdom) at 101 or 126 MHz. <sup>19</sup>F NMR spectra were recorded on a 400-MHz spectrometer at 470 MHz. Chemical shifts ( $\delta$ ) are reported in parts per million (ppm) downfield from tetramethylsilane and for <sup>1</sup>H NMR are referenced to residual proton in the NMR solvent (CDCl<sub>3</sub> =  $\delta$  7.26 ppm).

$^{13}\text{C}$  NMR are referenced to the residual solvent peak ( $\text{CDCl}_3 = \delta 77.16$  ppm). All  $^{13}\text{C}$  spectra are  $^1\text{H}$  decoupled. NMR data are represented as follows: chemical shift ( $\delta$  ppm), integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = double doublet, m = multiplet, app. d = apparent doublet, app. t. = apparent triplet), coupling constant ( $J$ ) in Hertz (Hz). High resolution mass spectra [electrospray ionisation (ESI-TOF)] (HRMS) were measured on a micromass LCT orthogonal time-of-flight mass spectrometer with leucine enkephalin (Tyr-Gly-Phe-Leu) as an internal lock mass. Infrared spectra were recorded on a FT-IR spectrometer and are reported in terms of wavenumbers ( $\nu_{\text{max}}$ ) with units of reciprocal centimetres ( $\text{cm}^{-1}$ ). Microwave experiments were conducted in a CEM Discover S-class microwave reactor with controlled irradiation at 2.45 GHz using standard microwave process Pyrex vials. Reaction time reflects time at the set reaction temperature maintained by cycling of irradiation (fixed hold times). Optical rotation ( $\alpha$ ) values were measured at room temperature and specific rotation ( $[\alpha]_{\text{D}}^{20}$ ) values are given in  $\text{deg}\cdot\text{dm}^{-1}\cdot\text{cm}^3\cdot\text{g}^{-1}$ . Melting points were determined in open capillary tubes. HPLC analysis was carried out on a Shimadzu LC-10AT<sub>VP</sub> machine and Shimadzu LC-2010A machine equipped with a UV-Vis detector employing Chiralcel<sup>®</sup> OD (Sigma Aldrich) and AD columns from Diacel Chemical Industries (Illkirch, France).

### 3.1. 4-Chloro-Ferrocenylbutanone (**10**)

Ferrocene **9** (12.7 g, 68 mmol) was added to a dry 500-mL two-necked room-bottom flask (RBF) containing a magnetic stir bar under an inert atmosphere. Dry  $\text{CH}_2\text{Cl}_2$  (120 mL) was added to the reaction flask which was cooled to 0 °C. 4-Chlorobutyryl chloride (95%, 7.3 mL, 62 mmol) was added to the reaction mixture followed by the slow addition of aluminium chloride (9.9 g, 74 mmol). The reaction mixture was warmed to room temperature and stirred for 18 h. Ice-cold  $\text{H}_2\text{O}$  (100 mL) was added to reaction mixture followed by 10%  $\text{Na}_2\text{S}_2\text{O}_4$  solution (100 mL). The mixture was stirred for 30 min and the aqueous layer was extracted with  $\text{CH}_2\text{Cl}_2$  ( $4 \times 50$  mL). The combined organic layers were washed with NaOH (2 M, 100 mL) and brine (100 mL), and dried with anhydrous  $\text{Na}_2\text{SO}_4$ . The solvent was removed in vacuo, and the crude product was purified by silica gel column chromatography (pentane/EtOAc) to yield **10** as an orange solid (17.3 g, 96%). Spectroscopic data are in good accordance to literature [14].

### 3.2. (R)-4-Chloro-1-Ferrocenylbutanol ((R)-**11**)

$\text{BH}_3\cdot\text{THF}$  (3 mL, 1.0 M, 3 mmol) was added to (S)-(-)-2-methyl-CBS-oxazaborolidine (crude residue) in a 250 mL Schlenk flask containing a magnetic stir bar under an inert atmosphere, and the reaction flask was cooled to -55 °C. A solution of 4-Chloroferrocenylbutanone (**11**) (3.67 g, 12.6 mmol) in dry THF (90 mL) was added followed by another portion of  $\text{BH}_3\cdot\text{THF}$  (1.0 M, 6 mL, 6 mmol). The reaction mixture was stirred for 18 h. The reaction mixture was warmed to 0 °C and then quenched by slow dropwise addition of MeOH (20 mL). The solvent was removed in vacuo, and the crude product was purified by silica gel column chromatography (pentane/EtOAc) to yield (R)-**11** as an orange oil (3.12 g, >99%, 94.5% ee). Spectroscopic data are in good accordance with the literature [14].

### 3.3. (R)-4-Chloro-2-Acetoxy-1-Ferrocenylbutane ((R)-**12**)

(R)-4-Chloro-1-ferrocenylbutanol ((R)-**11**) (3.60 g, 12.3 mmol), 4-dimethylaminopyridine (0.075 mg, 0.62 mmol) and triethylamine (75 mL) were added to a dry 300-mL RBF containing a magnetic stir bar under an inert atmosphere. Acetic anhydride (1.76 mL, 18.6 mmol) was added to the reaction flask which was stirred at room temperature for 18 h.  $\text{Et}_2\text{O}$  (100 mL) was added to reaction mixture which was subsequently washed with  $\text{H}_2\text{O}$  (100 mL), 10% aqueous  $\text{NH}_4\text{Cl}$  ( $2 \times 40$  mL),  $\text{H}_2\text{O}$  (50 mL) and dried with anhydrous  $\text{Na}_2\text{SO}_4$ . The reaction mixture was filtered, and the solvent was removed in vacuo. The resultant crude orange oil was used directly in the next step without further purification.

### 3.4. (R)-N-Allyl-Pyrrolidin-2'-ylferrocene ((R)-13)

(R)-4-Chloro-2-acetoxy-1-ferrocenylbutane (4.20 g, 12.5 mmol), allylamine (6.0 mL, 80.0 mmol) and dry MeOH (6.0 mL) were added to a dry sealed microwave vial containing a magnetic stir bar under an inert atmosphere. The reaction mixture was heated to reflux, stirred for 4 h then diluted with Et<sub>2</sub>O (10 mL), washed with sat. aqueous NaHCO<sub>3</sub> (2 × 10 mL), brine (10 mL) and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed in vacuo and the crude product was purified by alumina column chromatography (pentane/EtOAc, 30:1 with 1% triethylamine) to yield (R)-13 as an orange oil (3.61 g, 97%, 92.2% ee). Spectroscopic data are in good accordance with the literature [14].

### 3.5. 2-[(2R)-N-Allyl-Pyrrolidin-2'-yl]-(1S)-Diphenylphosphineferrocene (14) and 2-[(2R)-N-Allyl-Pyrrolidin-2'-yl]-(1R)-Diphenylphosphineferrocene (14)

(R)-N-allyl-pyrrolidin-2'-ylferrocene ((R)-13) (4.20 g, 12.5 mmol) and dry Et<sub>2</sub>O (6.0 mL) were added to a dry 250-mL RBF containing a magnetic stir bar under an inert atmosphere. The reaction mixture was cooled to −78 °C and *s*-BuLi (6.0 mL, 80.0 mmol) was added dropwise. After stirring for 3 h, the reaction mixture was warmed to 0 °C and stirred for an additional 1 h. Ph<sub>2</sub>PCl (6.0 mL, 80.0 mmol) was added, and the reaction mixture was stirred for 1.5 h and then quenched with aqueous NH<sub>4</sub>Cl (10%, 15 mL). The aqueous layer was separated and washed with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 mL) brine (10 mL) and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed in vacuo and the crude product was purified by silica gel column chromatography (pentane/EtOAc, 10:1 to 2:1) then alumina column chromatography (pentane/EtOAc with 0.1% triethylamine, 40:1 to 15:1) to yield (*R,S<sub>p</sub>*)-14 as an orange solid (0.79 g, 24%, 93% *d.e.*) and (*R,R<sub>p</sub>*)-14 as an orange solid (1.08 g, 33%, >99% *d.e.*). (*R,S<sub>p</sub>*)-14 (0.56 g) was dissolved in 4.5 mL pentane then cooled to −20 °C for 30 min. The precipitate was filtered, washed with pentane, dried and collected to yield (*R,S<sub>p</sub>*)-14 as an orange solid (0.43 g, >99% *d.e.*).

#### 3.5.1. Spectroscopic Analysis of (*R,S<sub>p</sub>*)-14

$R_f$  = 0.22 (pentane/EtOAc 10:1); m.p. = 136–138 °C;  $[\alpha]_D^{20}$  = −232.8 (*c* 0.63, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat):  $\nu_{\max}$  = 3054, 994 (C=C-H), 2939, 2922, 1443 (sp<sup>3</sup>C-H), 1628 (Alkene: C=C), 1609, 1587, 1565 (Aromatic: C=C) cm<sup>−1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.66–7.57 (m, 2H), 7.41–7.35 (m, 3H), 7.35–7.18 (m, 5H), 5.67–5.48 (m, 1H), 4.82 (d, *J* = 10.1 Hz, 1H), 4.74 (d, *J* = 17.1 Hz, 1H), 4.57 (s, 1H), 4.37 (t, *J* = 2.3 Hz, 1H), 3.96 (s, 5H), 3.46 (td, *J* = 8.0, 3.2 Hz, 1H), 3.12–2.99 (m, 1H), 2.91 (dd, *J* = 13.3, 5.2 Hz, 1H), 2.50–2.34 (m, 1H), 2.27–2.14 (m, 1H), 2.13–1.96 (m, 2H), 1.93–1.68 (m, 2H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  139.7 (d, *J* = 8.6 Hz), 137.9 (d, *J* = 8.5 Hz), 135.4 (d, *J* = 21.9 Hz), 132.9 (d, *J* = 18.9 Hz), 129.2, 128.2, 128.1 (d, *J* = 1.6 Hz), 128.1 (d, *J* = 1.6 Hz), 116.2, 75.4 (d, *J* = 8.7 Hz), 70.8 (d, *J* = 4.5 Hz), 70.8, 69.9, 69.7 (d, *J* = 4.3 Hz), 69.6, 62.1 (d, *J* = 9.5 Hz), 57.2, 54.0, 35.2, 22.6 ppm; <sup>31</sup>P NMR (202 MHz, CDCl<sub>3</sub>)  $\delta$  25.7 ppm; HRMS (ESI-TOF): calcd. for C<sub>29</sub>H<sub>31</sub>NPF<sub>e</sub> [M + H]<sup>+</sup> 480.1544; found 480.1536. See Supplementary Materials, pages 21–22 for <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P NMR spectra.

#### 3.5.2. Spectroscopic Analysis of (*R,R<sub>p</sub>*)-14

$R_f$  = 0.34 (pentane/EtOAc 9:1); m.p. = 110–112 °C;  $[\alpha]_D^{20}$  = 92.7 (*c* 0.4, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat):  $\nu_{\max}$  = 3048, 979 (C=C-H), 1611 (Alkene: C=C) cm<sup>−1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.66–7.48 (m, 2H), 7.45–7.31 (m, 3H), 7.29–7.11 (m, 5H), 5.69–5.49 (m, 1H), 5.12 (d, *J* = 16.8 Hz, 1H), 4.99 (d, *J* = 9.9 Hz, 1H), 4.44 (s, 1H), 4.28 (s, 1H), 3.97 (s, 4H), 3.87 (s, 2H), 3.40 (t, *J* = 7.8 Hz, 1H), 3.04 (t, *J* = 7.1 Hz, 1H), 2.66 (dd, *J* = 12.7, 8.2 Hz, 1H), 2.17–1.47 (m, 6H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  140.6 (d, *J* = 9.1 Hz), 138.5 (d, *J* = 9.2 Hz), 137.1, 135.4 (d, *J* = 21.7 Hz), 132.6 (d, *J* = 18.3 Hz), 129.1, 128.07 (d, *J* = 7.8 Hz), 127.9 (d, *J* = 6.2 Hz), 127.7, 115.9, 97.6 (d, *J* = 22.5 Hz), 73.3 (d, *J* = 11.8 Hz), 71.7 (d, *J* = 4.7 Hz), 71.0 (d, *J* = 5.1 Hz), 69.7, 68.6, 63.5 (d, *J* = 3.9 Hz), 58.2, 54.6, 35.3 (d, *J* = 7.6 Hz), 22.8 (d, *J* = 1.2 Hz) ppm; <sup>31</sup>P NMR (202 MHz, CDCl<sub>3</sub>)  $\delta$  22.98 ppm; HRMS (ESI-TOF): calcd. for C<sub>29</sub>H<sub>31</sub>NPF<sub>e</sub> [M + H]<sup>+</sup> 480.1544; found 480.1563. See Supplementary Materials, pages 23–24 for <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P NMR spectra.

### 3.6. 2-[(2R)-N-H-Pyrrolidin-2'-yl]-(1S)-Diphenylphosphineferrocene ((R,S<sub>p</sub>)-15)

2-[(2R)-N-allyl-pyrrolidin-2'-yl]-(1S)-diphenylphosphineferrocene (R,S<sub>p</sub>)-14 (0.41 g, 0.85 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (18.8 mg, 80.0 mmol), 1,3-dimethylbarbituric acid (NDMBA) (0.42 g, 2.69 mmol) and dry CH<sub>2</sub>Cl<sub>2</sub> (9.0 mL) were added to a dry 50-mL Schlenk flask containing a magnetic stir bar under an inert atmosphere. The reaction mixture was heated to 35 °C, stirred for 5 h, and then quenched with sat. aqueous NaHCO<sub>3</sub> (10 mL). The organic layer was separated and washed with sat. aqueous NaHCO<sub>3</sub> (10 mL) and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed in vacuo and the crude product was purified by alumina column chromatography (pentane/EtOAc/MeOH/ triethylamine, 3:1:0.1:0.01) to yield (R,S<sub>p</sub>)-15 as a yellow solid (0.37 g, 98%).

#### Spectroscopic Analysis of (R,S<sub>p</sub>)-15

R<sub>f</sub> = 0.37 (pentane/EtOAc/MeOH, 3:1:0.1); m.p. = 131–132 °C; [α]<sub>D</sub><sup>20</sup> = −184.4 (c 0.8, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat): ν<sub>max</sub> = 3049, 990 (C=C-H), 2989, 1432 (sp<sup>3</sup>C-H), 1662 (Alkene: C=C) cm<sup>−1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.59–7.46 (m, 2H), 7.42–7.33 (m, 3H), 7.31–7.15 (m, 5H), 4.46 (s, 1H), 4.34–4.20 (m, 2H), 4.04 (s, 5H), 3.74–3.66 (m, 1H), 2.93 (dd, J = 14.1, 7.7 Hz, 1H), 2.76 (dd, J = 15.3, 8.2 Hz, 1H), 2.27–2.09 (m, 1H), 2.03–1.70 (m, 3H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 140.2 (d, J = 10.0 Hz), 137.4 (d, J = 8.9 Hz), 135.4 (d, J = 20.9 Hz), 132.7 (d, J = 18.4 Hz), 129.2, 128.4 (d, J = 6.1 Hz), 128.3, 128.2, 96.04 (d, J = 22.8 Hz), 75.8 (d, J = 6.5 Hz), 71.4 (d, J = 4.0 Hz), 69.6, 69.5, 69.1 (d, J = 3.9 Hz), 56.4, 56.3, 47.0, 31.6, 25.3 ppm; <sup>31</sup>P NMR (202 MHz, CDCl<sub>3</sub>) δ 23.6 ppm; HRMS (ESI-TOF): calcd. for C<sub>26</sub>H<sub>27</sub>NPFe [M + H]<sup>+</sup> 440.1231; found 440.1243. See Supplementary Materials, pages 25–26 for <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P NMR spectra.

### 3.7. 2-[(2R)-N-H-Pyrrolidin-2'-yl]-(1R)-Diphenylphosphineferrocene-(R,R<sub>p</sub>)-15

Prepared according to the same procedure as for (R,S<sub>p</sub>)-15 using (R,R<sub>p</sub>)-14 (1.80 g, 3.75 mmol), to afford the product as a yellow solid (1.42 g, 86%).

#### 3.7.1. Spectroscopic Analysis of (R,R<sub>p</sub>)-15

R<sub>f</sub> = 0.37 (pentane/EtOAc/MeOH, 3:1:0.1); m.p. = 139–140 °C; [α]<sub>D</sub><sup>20</sup> = 239.0 (c 0.75, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat): ν<sub>max</sub> = 3054, 997 (C=C-H), 2987, 1444 (sp<sup>3</sup>C-H), 1636, 1590 (Aromatic: C=C) cm<sup>−1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.61–7.44 (m, 2H), 7.41–7.33 (m, 3H), 7.30–7.13 (m, 5H), 4.50 (s, 1H), 4.30–4.16 (m, 2H), 4.07 (s, 5H), 3.77–3.66 (m, 1H), 3.13 (dd, J = 13.3, 8.4 Hz, 1H), 2.93 (dd, J = 16.4, 7.7 Hz, 1H), 2.18 (s, 1H), 1.84–1.45 (m, 3H), 1.21–1.02 (m, 1H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 140.3 (d, J = 9.9 Hz), 137.4 (d, J = 9.0 Hz), 135.1 (d, J = 20.9 Hz), 132.7 (d, J = 18.5 Hz), 129.1, 128.2, 128.2, 128.1 (d, J = 2.9 Hz), 98.4 (d, J = 22.5 Hz), 74.8 (d, J = 7.6 Hz), 71.1 (d, J = 4.4 Hz), 69.5, 69.0, 67.8 (d, J = 4.1 Hz), 56.7 (d, J = 11.3 Hz), 46.8, 34.9, 25.9 ppm; <sup>31</sup>P NMR (202 MHz, CDCl<sub>3</sub>) δ 23.9 ppm; HRMS (ESI-TOF): calcd. for C<sub>26</sub>H<sub>27</sub>NPFe [M + H]<sup>+</sup> 440.1231; found 440.1209. See Supplementary Materials, pages 27–28 for <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P NMR spectra.

#### 3.7.2. Typical Procedure A: Phosphine-Coupling

(R,S<sub>p</sub>)-15 or (R,R<sub>p</sub>)-15 (1.0 equiv.), Et<sub>3</sub>N (3.0 equiv.) and dry toluene (0.23 M) were added to a dry 25-mL Schlenk flask containing a magnetic stir bar under an inert atmosphere. The di-substituted chlorophosphine (1.0 equiv.) in dry toluene (0.23 M) was added, and the reaction mixture was stirred at room temperature for 18 h. Heptane (5 mL) was added, and the reaction mixture was filtered. The solvent was removed in vacuo and the crude product was purified by alumina column chromatography (pentane/EtOAc, 99:1 to pentane/EtOAc/MeOH, 3:1:0.1) to yield the product.

### 3.8. 2-[(2R)-N-Diphenylphosphine-Pyrrolidin-2'-yl]-(1S)-Diphenylphosphineferrocene (L1)

Prepared according to typical procedure A using chlorodiphenylphosphine (0.075 g, 0.340 mmol) to afford the product as an orange solid (0.165 g, 78%).

### Spectroscopic Analysis of L1

$R_f = 0.80$  (pentane/EtOAc, 20:1); m.p. = 58–60 °C;  $[\alpha]_D^{20} = -146.0$  (c 0.7, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat):  $\nu_{\max} = 3032$  (C=C-H), 2969, 1422 (sp<sup>3</sup>C-H) cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.67–7.58 (m, 2H), 7.40–7.34 (m, 3H), 7.29–7.13 (m, 10H), 7.11–6.99 (m, 5H), 4.78–4.66 (m, J = 7.1, 3.4 Hz, 1H), 4.49 (d, J = 1.1 Hz, 1H), 4.36 (t, J = 2.4 Hz, 1H), 3.92 (s, 5H), 3.09 (dtd, J = 10.0, 7.3, 2.6 Hz, 1H), 2.78–2.63 (m, 1H), 2.45–2.16 (m, 2H), 1.90–1.70 (m, 1H), 1.55–1.34 (m, 1H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  140.0 (d, J = 7.8 Hz, 2C), 139.7 (d, J = 22.8 Hz), 139.1 (d, J = 9.1 Hz), 135.6 (d, J = 22.2 Hz, 2C), 133.0 (d, J = 21.0 Hz, 2C), 132.8 (d, J = 17.7 Hz), 132.8 (d, J = 17.7 Hz), 131.4 (d, J = 18.5 Hz, 2C), 129.1, 128.4, 128.1 (d, J = 8.1 Hz, 2C), 127.9 (d, J = 6.1 Hz, 2C), 127.8 (d, J = 5.3 Hz, 2C), 127.7 (d, J = 6.0 Hz, 2C), 127.4, 127.4, 99.3 (dd, J = 24.7, 5.4 Hz), 75.8 (d, J = 10.0 Hz), 71.4 (d, J = 4.4 Hz), 69.8 (dd, J = 4.4, 2.5 Hz), 69.7, 69.6 (5C), 60.9 (dd, J = 31.1, 10.0 Hz), 47.7 (d, J = 10.0 Hz), 36.6 (d, J = 6.8 Hz), 26.0 ppm; <sup>31</sup>P NMR (202 MHz, CDCl<sub>3</sub>)  $\delta$  44.8 (d, J = 16.4 Hz), -24.3 (d, J = 16.4 Hz) ppm; HRMS (ESI-TOF): calcd. for C<sub>38</sub>H<sub>36</sub>NP<sub>2</sub>Fe [M + H]<sup>+</sup> 624.1672; found 624.1650. See Supplementary Materials, pages 29–31 for <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P and <sup>31</sup>P-<sup>31</sup>P COSY NMR spectra.

### 3.9. 2-[(2R)-N-Bis(2-Methylphenyl)phosphine-Pyrrolidin-2'-yl]-(1S)-Diphenylphosphineferrocene (L2)

Prepared according to typical procedure A using bis(2-methylphenyl)chlorophosphine (0.057 g, 0.230 mmol) to afford the product as an orange solid (0.063 g, 42%).

### Spectroscopic Analysis of L2

$R_f = 0.79$  (pentane/EtOAc 10:1); m.p. = 84–87 °C;  $[\alpha]_D^{20} = -220.7$  (c 0.18, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat):  $\nu_{\max} = 3047$ , 923 (C=C-H), 2921, 2858, 1444 (sp<sup>3</sup>C-H), 1586, 1563, 1502 (Aromatic: C=C) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.65–7.54 (m, 2H), 7.40–7.28 (m, 4H), 7.23–6.89 (m, 11H), 6.74 (dd, J = 7.3, 2.6 Hz, 1H), 4.95–4.84 (m, 1H), 4.47 (d, J = 1.1 Hz, 1H), 4.31 (t, J = 2.4 Hz, 1H), 4.03–3.95 (m, 1H), 3.86 (s, 5H), 3.12 (dd, J = 16.7, 6.8 Hz, 1H), 2.68–2.31 (m, 3H), 2.25 (s, 3H), 1.99–1.83 (m, 1H), 1.69 (s, 3H), 1.65–1.45 (m, 1H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  142.0 (d, J = 27.9 Hz), 140.5 (dd, J = 7.3, 1.3 Hz), 140.2 (d, J = 25.5 Hz), 139.8 (dd, J = 9.7, 2.1 Hz), 139.0 (d, J = 11.5 Hz), 136.9 (d, J = 18.2 Hz), 135.6 (d, J = 22.6 Hz, 2C), 132.4 (d, J = 17.2 Hz), 132.4 (d, J = 17.2 Hz), 131.4 (d, J = 1.1 Hz), 131.0 (d, J = 3.2 Hz), 129.8 (d, J = 24.6 Hz), 129.8 (d, J = 24.2 Hz), 128.9, 128.0 (d, J = 27.5 Hz, 2C), 127.8, 127.3 (d, J = 12.5 Hz, 2C), 127.3, 126.8, 125.1 (d, J = 15.2 Hz, 2C), 100.1 (dd, J = 25.5, 2.7 Hz), 75.8 (d, J = 10.7 Hz), 71.2 (d, J = 4.6 Hz), 69.8, 69.4 (5C), 69.0 (d, J = 4.3 Hz), 60.3 (dd, J = 32.9, 10.4 Hz), 48.7 (d, J = 9.9 Hz), 36.5 (dd, J = 6.5, 1.9 Hz), 26.9, 21.3 (dd, J = 20.8, 1.4 Hz), 20.7 (d, J = 18.8 Hz) ppm; <sup>31</sup>P NMR (202 MHz, CDCl<sub>3</sub>)  $\delta$  31.6 (d, J = 26.0 Hz), -24.8 (d, J = 26.0 Hz) ppm; HRMS (ESI-TOF): calcd. for C<sub>40</sub>H<sub>40</sub>NP<sub>2</sub>Fe [M + H]<sup>+</sup> 652.1985; found 652.1993. See Supplementary Materials, pages 32–33 for <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P NMR spectra.

### 3.10. 2-[(2R)-N-Bis(4-fluorophenyl)phosphine-Pyrrolidin-2'-yl]-(1S)-Diphenylphosphineferrocene (L3)

Prepared according to typical procedure A using bis(4-fluorophenyl)chlorophosphine (0.054 g, 0.210 mmol) to afford the product as a yellow solid (0.072 g, 50%).

### Spectroscopic Analysis of L3

$R_f = 0.655$  (pentane/EtOAc, 20:1); m.p. = 72–74 °C;  $[\alpha]_D^{20} = -166.0$  (c 0.2, CHCl<sub>3</sub>); IR (neat):  $\nu_{\max} = 3022$ , 982 (C=C-H), 2936, 2911, 1486 (sp<sup>3</sup>C-H), 1647 (Alkene: C=C) cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.67–7.57 (m, 2H), 7.41–7.34 (m, 3H), 7.26–7.18 (m, 2H), 7.10–6.82 (m, 11H), 4.83–4.68 (m, 1H), 4.43 (s, 1H), 4.38 (t, J = 2.4 Hz, 1H), 4.03 (d, J = 1.0 Hz, 1H), 3.91 (s, 5H), 3.10–2.96 (m, 1H), 2.76–2.64 (m, 1H), 2.41–2.15 (m, 2H), 1.88–1.72 (m, 1H), 1.55–1.37 (m, 1H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  164.1, 163.5, 162.1, 161.5, 139.9–139.7 (m), 138.7 (dd, J = 8.8, 1.3 Hz), 135.4 (d, J = 22.2 Hz, 2C), 134.6 (d, J = 22.7 Hz), 134.6 (d, J = 22.5 Hz), 133.0 (d, J = 19.8 Hz), 132.9 (d, J = 19.8 Hz), 132.7 (d, J = 17.8 Hz), 132.7 (d, J = 17.7 Hz), 129.0, 128.0 (d, J = 8.2 Hz, 2C), 127.5 (d, J = 6.1 Hz, 2C), 127.3, 115.0 (d,

$J = 6.7$  Hz), 114.9 (d,  $J = 5.9$  Hz), 114.8 (d,  $J = 6.7$  Hz), 114.7 (d,  $J = 5.8$  Hz), 98.5 (dd,  $J = 25.2$ , 6.3 Hz), 75.8 (d,  $J = 10.8$  Hz), 71.38 (d,  $J = 4.6$  Hz), 69.67, 69.47 (5C), 69.34 (dd,  $J = 4.4$ , 2.2 Hz), 60.85 (dd,  $J = 31.6$ , 10.6 Hz), 47.2 (d,  $J = 10.0$  Hz), 35.9 (d,  $J = 3.9$  Hz), 25.7 ppm;  $^{19}\text{F}$  NMR (470 MHz,  $\text{CDCl}_3$ )  $\delta$  -113.1–113.2 (m), -114.7–114.8 (m) ppm;  $^{31}\text{P}$  NMR (202 MHz,  $\text{CDCl}_3$ )  $\delta$  43.1 (dt,  $J = 19.5$ , 5.4 Hz), -25.1 (d,  $J = 19.5$  Hz) ppm; HRMS (ESI-TOF): calcd. for  $\text{C}_{38}\text{H}_{33}\text{NP}_2\text{F}_2\text{Fe} [\text{M} + \text{H}]^+$  660.1484; found 660.1481. See Supplementary Materials, pages 34–36 for  $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{31}\text{P}$  and  $^{19}\text{F}$  NMR spectra.

### 3.11. 2-[(2R)-N-Bis(3,5-Di-Trifluoromethylphenyl)phosphine-Pyrrolidin-2'-yl]-(1S)-Diphenylphosphineferrocene (L4)

Prepared according to typical procedure A using bis(3,5-di-trifluoromethylphenyl)chlorophosphine (0.103 g, 0.210 mmol) to afford the product as an orange solid (0.075 g, 40%).

#### Spectroscopic Analysis of L4

$R_f = 0.37$  (pentane/EtOAc/MeOH, 3:1:0.1); m.p. = 56–58 °C;  $[\alpha]_D^{20} = -184.3$  (c 0.08,  $\text{CH}_2\text{Cl}_2$ ); IR (neat):  $\nu_{\text{max}} = 3053, 987$  (C=C-H), 2970, 1434 ( $\text{sp}^3\text{C-H}$ ), 1587, 1576 (Aromatic: C=C)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.76 (s, 2H), 7.68–7.57 (m, 2H), 7.44–7.33 (m, 7H), 7.27–7.17 (m, 2H), 6.93–6.83 (m, 3H), 5.07–4.94 (m, 1H), 4.51 (t,  $J = 2.4$  Hz, 1H), 4.43 (s, 1H), 4.21 (t,  $J = 2.9$  Hz, 1H), 3.91 (s, 5H), 2.89 (dd,  $J = 16.4$ , 8.3 Hz, 1H), 2.74–2.60 (m, 1H), 2.57–2.41 (m, 1H), 2.34–2.15 (m, 1H), 2.02–1.85 (m, 1H), 1.82–1.65 (m, 1H) ppm;  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  142.1 (d,  $J = 1.0$  Hz), 141.9 (d,  $J = 1.3$  Hz), 141.6, 141.4, 138.9 (dd,  $J = 6.1$ , 1.8 Hz), 138.3 (dd,  $J = 7.8$ , 1.7 Hz), 135.3 (d,  $J = 22.4$  Hz, 2C), 132.9 (d,  $J = 18.6$  Hz), 132.8 (d,  $J = 18.6$  Hz), 131.8–131.7 (m), 131.7–131.5 (m), 131.4 (d,  $J = 4.7$  Hz), 131.3–131.1 (m, 2C), 131.0–130.9 (m,  $J = 23.5$  Hz), 129.1, 128.1 (d,  $J = 8.4$  Hz, 2C), 127.6, 127.3 (d,  $J = 6.7$  Hz, 2C), 122.6–122.4 (m), 122.2–121.9 (m), 96.6 (dd,  $J = 26.5$ , 5.9 Hz), 76.5 (dd,  $J = 10.0$ , 1.4 Hz), 72.0 (d,  $J = 4.7$  Hz), 70.6, 69.7 (5C), 68.4 (d,  $J = 3.5$  Hz), 60.9 (dd,  $J = 32.6$ , 12.7 Hz), 47.3 (d,  $J = 10.8$  Hz), 35.3 (d,  $J = 5.5$  Hz), 26.0 ppm;  $^{19}\text{F}$  NMR (470 MHz,  $\text{CDCl}_3$ )  $\delta$  -62.3, -61.0 ppm;  $^{31}\text{P}$  NMR (202 MHz,  $\text{CDCl}_3$ )  $\delta$  40.1 (d,  $J = 26.2$  Hz), -27.1 (d,  $J = 26.2$  Hz) ppm; HRMS (ESI-TOF): calcd. for  $\text{C}_{42}\text{H}_{32}\text{NP}_2\text{F}_{12}\text{Fe} [\text{M} + \text{H}]^+$  896.1168; found 896.1155. See Supplementary Materials, pages 37–39 for  $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{31}\text{P}$  and  $^{19}\text{F}$  NMR spectra.

### 3.12. 2-[(2R)-N-(R)-1,1'-Binaphthyl-2,2'-Diylphosphoro-Pyrrolidin-2'-yl]-(1S)-Diphenylphosphineferrocene (L5)

Prepared according to typical procedure A using (R)-1,1'-binaphthyl-2,2'-diyl phosphorochloridate (0.21 g, 0.60 mmol, 1.3 equiv.) to afford the product as a yellow solid (0.29 g, 83%).

#### Spectroscopic Analysis of L5

$R_f = 0.47$  (pentane/EtOAc, 9:1); m.p. = 219–220 °C;  $[\alpha]_D^{20} = -241.2$  (c 0.29,  $\text{CH}_2\text{Cl}_2$ ); IR (neat):  $\nu_{\text{max}} = 3054, 896$  (C=C-H), 2987, 1421 ( $\text{sp}^3\text{C-H}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.93–7.78 (m, 4H), 7.67–7.57 (m, 2H), 7.47–7.27 (m, 10H), 7.25–7.13 (m, 5H), 6.92 (d,  $J = 8.8$  Hz, 1H), 5.24–5.11 (m, 1H), 4.45 (s, 1H), 4.35 (d,  $J = 2.3$  Hz, 1H), 3.96 (s, 5H), 3.90 (s, 1H), 2.86–2.70 (m, 1H), 2.66–2.54 (m, 1H), 2.51–2.27 (m, 2H), 1.87–1.60 (m, 2H) ppm;  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  150.4, 149.9, 140.4 (d,  $J = 8.9$  Hz), 138.5 (d,  $J = 6.4$  Hz), 135.6 (d,  $J = 22.1$  Hz, 2C), 132.7, 132.6 (d,  $J = 1.6$  Hz), 132.5 (d,  $J = 1.9$  Hz), 132.4 (d,  $J = 2.0$  Hz), 131.20, 130.4, 129.8, 129.4, 129.1, 128.4, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.4, 127.3, 127.0 (2C), 125.8 (d,  $J = 10.9$  Hz, 2C), 124.5, 124.3, 124.3, 123.91–123.81 (m), 122.3 (d,  $J = 1.8$  Hz), 122.2 (d,  $J = 1.6$  Hz), 121.9, 97.1 (dd,  $J = 24.4$ , 7.4 Hz), 75.5 (d,  $J = 11.2$  Hz), 71.5 (d,  $J = 4.4$  Hz), 69.7–69.6 (m, 6C), 69.5, 56.1 (dd,  $J = 33.6$ , 8.8 Hz), 44.0 (d,  $J = 6.8$  Hz), 34.0, 25.34 ppm;  $^{31}\text{P}$  NMR (202 MHz,  $\text{CDCl}_3$ )  $\delta$  146.9 (d,  $J = 56.2$  Hz), -23.8 (d,  $J = 56.2$  Hz) ppm; HRMS (ESI-TOF): calcd. for  $\text{C}_{46}\text{H}_{38}\text{NO}_2\text{P}_2\text{Fe} [\text{M} + \text{H}]^+$  754.1727; found 754.1719. See Supplementary Materials, pages 40–41 for  $^1\text{H}$ ,  $^{13}\text{C}$ , and  $^{31}\text{P}$  NMR spectra and page 40 for X-ray crystallographic data.

### 3.13. 2-[(2R)-N-(S)-1,1'-Binaphthyl-2,2'-Diylphosphoro-Pyrrolidin-2'-yl]-(1S)-Diphenylphosphineferrocene (L6)

Prepared according to typical procedure A using (S)-1,1'-binaphthyl-2,2'-diyl phosphorochloridate (0.10 g, 0.29 mmol, 1.2 equiv.) to afford the product as a yellow solid (0.12 g, 70%).

#### Spectroscopic Analysis of L6

$R_f = 0.83$  (pentane/EtOAc, 4:1); m.p. = 208–209 °C;  $[\alpha]_D^{20} = -32.5$  (c 0.17, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat):  $\nu_{\max} = 2939, 2926, 1443$  (sp<sup>3</sup>C-H), 1613, 1588, 1503 (Aromatic: C=C) cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.92–7.81 (m, 4H), 7.65–7.55 (m, 2H), 7.43–7.33 (m, 6H), 7.30–7.19 (m, 9H), 7.15 (d,  $J = 8.7$  Hz, 1H), 5.07–4.93 (m, 1H), 4.60 (s, 1H), 4.42 (t,  $J = 2.4$  Hz, 1H), 4.01–3.97 (m, 1H), 3.95 (s, 5H), 3.03–2.91 (m, 1H), 2.56–2.42 (m, 1H), 2.39–2.23 (m, 2H), 1.82–1.67 (m, 1H), 1.64–1.49 (m, 1H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  150.1 (d,  $J = 6.2$  Hz), 149.8 (d,  $J = 1.8$  Hz), 139.6 (d,  $J = 8.2$  Hz), 138.5 (d,  $J = 9.1$  Hz), 135.4 (d,  $J = 22.1$  Hz, 2C), 132.8 (d,  $J = 4.4$  Hz), 132.8, 132.6 (d,  $J = 2.8$  Hz), 132.6 (d,  $J = 1.0$  Hz), 131.1, 130.9, 130.6, 129.8, 129.4, 129.1, 128.8, 128.2, 128.1, 128.1, 128.0, 127.9, 127.9, 127.6, 126.9 (d,  $J = 9.1$  Hz, 2C), 125.8 (d,  $J = 8.2$  Hz, 2C), 124.4 (d,  $J = 7.6$  Hz, 2C), 123.8, 122.9, 122.2, 122.2 (d,  $J = 1.5$  Hz), 98.0 (dd,  $J = 24.2, 7.7$  Hz), 75.6 (d,  $J = 11.2$  Hz), 71.6 (d,  $J = 4.4$  Hz), 69.7 (dd,  $J = 4.0, 2.2$  Hz), 69.6 (5C), 68.2, 57.3 (dd,  $J = 35.3, 9.7$  Hz), 44.1 (d,  $J = 4.8$  Hz), 34.7, 26.0 ppm; <sup>31</sup>P NMR (202 MHz, CDCl<sub>3</sub>)  $\delta$  150.8 (d,  $J = 29.3$  Hz), -24.7 (d,  $J = 29.3$  Hz) ppm; HRMS (ESI-TOF): calcd. for C<sub>46</sub>H<sub>38</sub>NO<sub>2</sub>P<sub>2</sub>Fe [M + H]<sup>+</sup> 754.1727; found 754.1757. See Supplementary Materials, pages 42–43 for <sup>1</sup>H, <sup>13</sup>C, and <sup>31</sup>P NMR spectra.

### 3.14. 2-[(2R)-N-(R)-1,1'-Binaphthyl-2,2'-Diylphosphoro-Pyrrolidin-2'-yl]-(1R)-Diphenylphosphineferrocene (L7)

Prepared according to typical procedure A using (R)-1,1'-binaphthyl-2,2'-diyl phosphorochloridate (0.15 g, 0.44 mmol, 1.3 equiv.) to afford the product as an orange solid (0.23 g, 90%).

#### Spectroscopic Analysis of L7

$R_f = 0.86$  (pentane/EtOAc 9:1); m.p. = 177–179 °C;  $[\alpha]_D^{20} = -83.5$  (c 0.18, CH<sub>2</sub>Cl<sub>2</sub>); IR (neat):  $\nu_{\max} = 3052, 947$  (C=C-H), 2967, 1434 (sp<sup>3</sup>C-H), 1588, 1567 (Aromatic: C=C) cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  8.04–7.83 (m, 5H), 7.68–7.55 (m, 3H), 7.47–7.35 (m, 8H), 7.33 (s, 1H), 7.31–7.26 (m, 3H), 7.25–7.19 (m, 2H), 5.32 (dd,  $J = 11.7, 7.4$  Hz, 1H), 4.51 (d,  $J = 1.4$  Hz, 1H), 4.31 (dd,  $J = 4.1, 1.7$  Hz, 1H), 4.15 (s, 5H), 3.98–3.92 (m, 1H), 3.07–2.90 (m, 1H), 2.79–2.60 (m, 1H), 2.00–1.81 (m, 1H), 1.56–1.32 (m, 3H) ppm; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  151.0 (d,  $J = 4.7$  Hz), 150.0, 140.3 (d,  $J = 9.1$  Hz), 137.6 (d,  $J = 8.0$  Hz), 135.3 (d,  $J = 21.6$  Hz, 2C), 132.8 (d,  $J = 15.6$  Hz), 132.5 (d,  $J = 18.1$  Hz, 2C), 131.4, 130.5, 130.3, 129.7, 129.2, 128.3, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.0 (d,  $J = 10.7$  Hz, 2C), 126.1 (d,  $J = 4.1$  Hz, 2C), 124.8, 124.4, 124.2 (d,  $J = 5.1$  Hz), 122.1 (d,  $J = 2.0$  Hz), 122.0 (2C), 99.9 (d,  $J = 28.1$  Hz), 71.9 (d,  $J = 10.4$  Hz), 71.5 (d,  $J = 4.1$  Hz), 70.2 (d,  $J = 4.7$  Hz), 70.0 (d,  $J = 5.7$  Hz, 5C), 68.5, 57.4 (dd,  $J = 34.8, 8.6$  Hz), 45.3 (d,  $J = 6.8$  Hz), 36.1 (t,  $J = 3.7$  Hz), 23.91 ppm; <sup>31</sup>P NMR (202 MHz, CDCl<sub>3</sub>)  $\delta$  148.1, -24.4 ppm; HRMS (ESI-TOF): calcd. for C<sub>46</sub>H<sub>38</sub>NO<sub>2</sub>P<sub>2</sub>Fe [M + H]<sup>+</sup> 754.1727; found 754.1719. See Supplementary Materials, pages 44–45 for <sup>1</sup>H, <sup>13</sup>C, and <sup>31</sup>P NMR spectra.

### 3.15. 2-[(2R)-N-(S)-1,1'-Binaphthyl-2,2'-Diylphosphoro-Pyrrolidin-2'-yl]-(1R)-Diphenylphosphineferrocene (L8)

Prepared according to typical procedure A using (S)-1,1'-binaphthyl-2,2'-diyl phosphorochloridate (0.15 g, 0.44 mmol, 1.3 equiv.) to afford the product as an orange solid (0.25 g, 98%).

#### 3.15.1. Spectroscopic Analysis of L8

$R_f = 0.91$  (pentane/EtOAc 9:1); m.p. = 185–187 °C;  $[\alpha]_D^{20} = 380.2$  (c 1.3, CHCl<sub>3</sub>); IR (neat):  $\nu_{\max} = 3067, 977$  (C=C-H), 1619 (Alkene: C=C) cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  8.04–7.90 (m, 5H), 7.70–7.52 (m, 4H), 7.50–7.34 (m, 8H), 7.33–7.26 (m, 3H), 7.25–7.22 (m, 2H), 5.33 (dd,  $J = 9.6, 7.9$  Hz, 1H), 4.68 (d,  $J = 1.3$  Hz, 1H), 4.41 (t,  $J = 2.2$  Hz, 1H), 4.18 (s,

5H), 4.01–3.95 (m, 1H), 3.27–3.11 (m, 1H), 2.53–2.40 (m, 1H), 1.79–1.61 (m, 1H), 1.55–1.34 (m, 2H), 1.23–1.12 (m, 1H) ppm;  $^{13}\text{C}$  NMR (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  150.1 (d,  $J = 6.5$  Hz), 149.9 (d,  $J = 2.1$  Hz), 140.3 (d,  $J = 9.2$  Hz), 137.61 (d,  $J = 8.1$  Hz), 135.2 (d,  $J = 21.5$  Hz, 2C), 132.9 (d,  $J = 1.3$  Hz), 132.7 (d,  $J = 1.1$  Hz), 132.5 (d,  $J = 18.3$  Hz, 2C), 131.3, 130.7, 130.3, 129.9, 129.2, 128.4, 128.2, 128.0, 128.1, 128.0, 128.0, 127.9, 127.0 (d,  $J = 21.6$  Hz, 2C), 126.1 (d,  $J = 4.9$  Hz, 2C), 124.6 (d,  $J = 5.2$  Hz, 2C), 123.8 (d,  $J = 4.9$  Hz), 123.3 (d,  $J = 2.3$  Hz), 122.0, 100.9 (dd,  $J = 24.9, 1.9$  Hz), 71.8 (d,  $J = 10.4$  Hz), 71.4 (d,  $J = 4.2$  Hz), 69.9 (d,  $J = 4.7$  Hz, 5C), 69.7 (d,  $J = 4.9$  Hz), 68.4, 59.5 (dd,  $J = 41.3, 9.3$  Hz), 44.0 (d,  $J = 5.9$  Hz), 36.0–35.3 (m), 24.6 ppm;  $^{31}\text{P}$  NMR (202 MHz,  $\text{CDCl}_3$ )  $\delta$  150.8,  $-24.7$  ppm; HRMS (ESI-TOF): calcd. for  $\text{C}_{46}\text{H}_{38}\text{NO}_2\text{P}_2\text{Fe}$   $[\text{M} + \text{H}]^+$  754.1727; found 754.1765. See Supplementary Materials, pages 46–48 for  $^1\text{H}$ ,  $^{13}\text{C}$  and  $^{31}\text{P}$  and  $^{31}\text{P}$ - $^{31}\text{P}$  COSY NMR spectra.

### 3.15.2. Rhodium-Catalyzed Asymmetric Hydrogenation

#### Preparation of Substrates/Characterization Data for Substrates and Products

The substrates for catalysis were prepared according to the literature procedures and all characterization data for the substrates and products were in accordance with those reported. **16a/17a–16c/7c** and **16e/17e** and **16g/17g**, [27] **16d/16d** and **16i/17i** and **17k** and **17a/19a–18e/19e**, [37] **16k** is commercially available, **16f/17f**, [38] **16h/17h** and **16j/17j**, [39] and **16f/17f** [24].

### 3.15.3. Rhodium-Catalyzed Asymmetric Hydrogenation of Dehydroamino Acid Esters

#### Typical Procedure B: Optimization and Substrate Scope

##### Optimization

The Rh source (0.005 mmol), ligand (0.006 mmol), substrate **16a–k** (0.5 mmol), and the solvent (2 mL) were added to a dry 10-mL Schlenk flask containing a magnetic stir bar under an inert atmosphere. The reaction mixture was cooled under liquid nitrogen, the atmosphere was evacuated (high vacuum), and then the reaction chamber was refilled with hydrogen using a balloon (reactions requiring higher pressures of hydrogen were quickly transferred to an autoclave). The reaction was stirred for the designated time, filtered through a plug of Celite<sup>®</sup>, and washed with the solvent of choice. The solvent was removed in vacuo to yield the crude product. The ee was determined by chiral HPLC and conversion of starting material to product by  $^1\text{H}$  NMR spectroscopy.

##### Substrate Scope

The reactions were performed with 0.5 mmol of the substrate using the procedure outlined above for the optimization process, with the following exceptions. Racemic reactions were performed with ( $\pm$ )-BINAP (1.1 mol %) using  $\text{Rh}(\text{COD})_2\text{OTf}$  (1.0 mol %), 2.3 bar  $\text{H}_2$  for substrate **16a** and 40 bar  $\text{H}_2$  for **16b–k**, in THF for 1–18 h at room temperature. Reactions with **L1** (1.1 mol %) were performed using  $\text{Rh}(\text{COD})_2\text{OTf}$  (1.0 mol %), 1 bar  $\text{H}_2$ , in THF for 12 h at room temperature. Reactions with **L4** (1.1 mol %) were performed using  $\text{Rh}(\text{COD})_2\text{OTf}$  (1.0 mol %), 1 bar  $\text{H}_2$ , in THF for 4 h at 0 °C. Reactions with **L7** (0.22 mol %) were performed using  $\text{Rh}(\text{COD})_2\text{OTf}$  (0.2 mol %), 10 bar  $\text{H}_2$ , in THF for 12 h at room temperature. For the methods and chiral columns used to determine the enantiomeric excess, and chromatograms for racemic and enantioenriched products, see Supporting Materials (Table S1) and pages 4–14, respectively.

#### 3.16. (*S*)-Methyl 2-Acetamido-3-Phenylpropanoate (**17a**)

Prepared according to typical procedure B to afford the product (>99 % conversion, 99.5% ee with **L7**) with all characterization analysis in good accordance with the literature.

#### 3.17. (*S*)-Methyl 2-Acetamido-3-(4-Methoxyphenyl)propanoate (**17b**)

Prepared according to typical procedure B to afford the product (>99% conversion, >99.9% ee with **L7**) with all characterization analysis in good accordance with the literature.



### 3.18. (S)-Methyl 2-Acetamido-3-(p-Tolyl)propanoate (17c)

Prepared according to typical procedure B to afford the product (>99 % conversion, 99.4 % ee with L7) with all characterization analysis in good accordance with the literature.

### 3.19. (S)-Methyl 2-Acetamido-3-(4-Chlorophenyl)propanoate (17d)

Prepared according to typical procedure B to afford the product (>99% conversion, 99.4% ee with L7) with all characterization analysis in good accordance with the literature.

### 3.20. (S)-Methyl 2-Acetamido-3-(4-Fluorophenyl)propanoate (17e)

Prepared according to typical procedure B to afford the product (>99% conversion, 98.5% ee with L7) with all characterization analysis in good accordance with the literature.

### 3.21. (S)-Methyl 2-Acetamido-3-(4-Nitrophenyl)propanoate (17f)

Prepared according to typical procedure B to afford the product (>99% conversion, 98.6% ee with L7) with all characterization analysis in good accordance with the literature.

### 3.22. (S)-Methyl 2-Acetamido-3-(3-Chlorophenyl)propanoate (17g)

Prepared according to typical procedure B to afford the product (>99% conversion, 99.4% ee with L7) with all characterization analysis in good accordance with the literature.

### 3.23. (S)-Methyl 2-Acetamido-3-(3-Bromophenyl)propanoate (17h)

Prepared according to typical procedure B to afford the product (>99% conversion, 99.0% ee with L7) with all characterization analysis in good accordance with the literature.

### 3.24. (S)-Methyl 2-Acetamido-3-(2-Chlorophenyl)propanoate (17i)

Prepared according to typical procedure B to afford the product (>99% conversion, 99.7% ee with L7) with all characterization analysis in good accordance with the literature.

### 3.25. (S)-Methyl 2-Acetamido-3-(Naphthalen-1-yl)propanoate (17j)

Prepared according to typical procedure B to afford the product (>99% conversion, 99.2% ee with L7) with all characterization analysis in good accordance with the literature.

### 3.26. (S)-Methyl 2-Acetamidopropanoate (17k)

Prepared according to typical procedure B to afford the product (>99% conversion, 99.1% ee with L7) with all characterization analysis in good accordance with the literature.

## 3.26.1. Rhodium-Catalyzed Asymmetric Hydrogenation of $\alpha$ -Aryl Enamides

### Typical Procedure C: Optimization and Substrate Scope

#### Optimization

Reactions were set up using a glovebox. Rh(COD)<sub>2</sub>OTf (0.005 mmol), ligand (0.006 mmol), *N*-(1-phenylvinyl)acetamide **18a** (0.108 g, 0.5 mmol), and the solvent (2 mL) were added to a dry 10-mL Schlenk flask containing a magnetic stir bar under an inert atmosphere. The reaction mixture was cooled under liquid nitrogen, the atmosphere was evacuated (high vacuum), and the reaction chamber was refilled with hydrogen (balloon, reactions requiring higher pressures of hydrogen were quickly transferred to an autoclave). The reaction was stirred for the designated time, filtered through a plug of Celite<sup>®</sup>, and washed with the solvent of choice. The solvent was removed in vacuo to yield the crude product. The ee was determined by HPLC and conversion of starting material to product by <sup>1</sup>H NMR spectroscopy.

#### Substrate Scope

The reactions were performed with 0.5 mmol of the substrate using the procedure outlined above for the optimization process, with the following exceptions. Racemic reactions were performed with ( $\pm$ )-BINAP (1.2 mol %) using Rh(COD)<sub>2</sub>OTf (1.0 mol %), 40 bar H<sub>2</sub> in THF for 18 h for substrate **18a** and Pd/C (1.0 mol %, 10 wt. % loading),

20 bar H<sub>2</sub> in methanol for 0.5–2 h for **18b–f**. Reactions with **L1** (1.1 mol %) were performed using Rh(COD)<sub>2</sub>OTf (1.0 mol %), 40 bar H<sub>2</sub>, in CH<sub>2</sub>Cl<sub>2</sub> for 24 h at room temperature. Reactions with **L4** (1.1 mol %) were performed using Rh(COD)<sub>2</sub>OTf (1.0 mol %), 20 bar H<sub>2</sub>, in MeOH for 1 h at room temperature. Reactions with **L7** (0.22 mol %) were performed using Rh(COD)<sub>2</sub>OTf (0.2 mol %), 10 bar H<sub>2</sub>, in THF for 1 h at room temperature except for substrate **18f**, which was subjected to Rh(COD)<sub>2</sub>OTf (1.0 mol %), **L7** (1.1 mol %), 60 bar H<sub>2</sub>, in THF for 2 h at room temperature. For the methods and chiral columns used to determine the enantiomeric excess, and chromatograms for racemic and enantioenriched products, see Supplementary Materials (Table S1) and pages 15–20, respectively.

### 3.27. (*S*)-*N*-(1-Phenylethyl)acetamide (**19a**)

Prepared according to typical procedure C to afford the product (>99% conversion, 96.4% ee with **L7**) with all characterization analysis in good accordance with the literature. The absolute configuration of the product was determined by comparison of the  $[\alpha]_D^{20}$  value to the literature [40]. Reference value;  $[\alpha]_D^{20} = 129.5$  (*c* 1.00, CHCl<sub>3</sub>) for the (*R*)-enantiomer (99% ee). Value obtained;  $[\alpha]_D^{20} = -52.7$  (*c* 0.33, CHCl<sub>3</sub>).

### 3.28. (*S*)-*N*-(1-(Naphthalen-2-yl)ethyl)acetamide (**19b**)

Prepared according to typical procedure B to afford the product (>99% conversion, 97.4% ee with **L7**) with all characterization analysis in good accordance with the literature.

### 3.29. (*S*)-*N*-(1-(4-Chlorophenyl)ethyl)acetamide (**19c**)

Prepared according to typical procedure B to afford the product (>99% conversion, 97.7% ee with **L7**) with all characterization analysis in good accordance with the literature.

### 3.30. (*S*)-*N*-(1-(4-Methoxyphenyl)ethyl)acetamide (**19d**)

Prepared according to typical procedure B to afford the product (>99% conversion, 93.7% ee with **L7**) with all characterization analysis in good accordance with the literature.

### 3.31. (*S*)-*N*-(1,2,3,4-Tetrahydronaphthalen-1-yl)acetamide (**19e**)

Prepared according to typical procedure B to afford the product (23% conversion, 48.0% ee with **L7**) with all characterization analysis in good accordance with the literature.

### 3.32. (*S*)-Ethyl 3-Acetamido-3-Phenylpropanoate (**19f**)

Prepared according to typical procedure B to afford the product (>99% conversion, 61.3% ee with **L1**) with all characterization analysis in good accordance with the literature.

## 4. Conclusions

In summary, we have reported the design and convenient modular synthesis of a series of novel *P,P*-ferrocenyl pyrrolidine-containing ligands. Through-space interphosphorus coupling was observed in the <sup>31</sup>P-NMR spectra for ligands **L1–6**, which bear (*S*)-planar chirality, indicative of a close P–P proximity in the solution phase. The potential application of the ligands was displayed in the rhodium-catalyzed asymmetric hydrogenation of dehydroamino acids and  $\alpha$ -aryl enamides with full conversion of the starting materials and excellent ee's observed in almost all cases using the BINOL-substituted phosphine-phosphoramidite **L7**. Further investigations of other catalytic asymmetric transformations are currently underway using these ligands, and progress will be reported in due course.

**Supplementary Materials:** The following are available online at <https://www.mdpi.com/article/10.3390/molecules27186078/s1>, including <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F, and <sup>31</sup>P NMR spectra for novel compounds (*R,S<sub>p</sub>*)-**14**, (*R,R<sub>p</sub>*)-**14**, (*R,S<sub>p</sub>*)-**15**, and (*R,R<sub>p</sub>*)-**15** and ligands **L1–L8**; Supercritical Fluid Chromatography chromatograms of racemic and enantioenriched compounds **17a–k** and **19a–f**; and X-ray crystallographic details of **L5**.

**Author Contributions:** Conceptualization, P.J.G.; synthetic methodology, X.L.; Investigation, X.L., T.B.B., and Y.O.; writing—original draft preparation, C.K.; writing—review and editing, P.J.G.; supervision, P.J.G.; project administration, P.J.G.; funding acquisition, P.J.G. All authors have read and agreed to the published version of the manuscript.

**Funding:** X.L. is grateful for the award of an IRCSET Postgraduate Research Scholarship. This publication has emanated from research conducted with the financial support of the Synthesis and Solid State Pharmaceutical Centre (SSPC), funded by Science Foundation Ireland (SFI) under grant numbers 12\RC\2275. C.K. is grateful for the award of an SSPC Ph.D. Scholarship. Acquisition of mass spectra was supported by a Science Foundation Ireland Infrastructure Award (18/RI/5702).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Acknowledgments:** Facilities were provided by the Centre for Synthesis and Chemical Biology (CSCB), funded by the Higher Education Authority's PRTLI. The authors wish to thank Yannick Ortin of the UCD NMR Centre in the School of Chemistry/CSCB for help with NMR spectroscopic studies and Jimmy Muldoon for the acquisition of mass spectra.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Samples of the compounds are not available from the authors.

## References

1. Jacobsen, E.N.; Pfaltz, A.; Yamamoto, H. (Eds.) *Comprehensive Asymmetric Catalyses*; Springer: Berlin, Heidelberg, Germany, 1999.
2. Ojima, I. (Ed.) *Catalytic Asymmetric Synthesis*, 3rd ed.; Wiley & Sons: New York, NY, USA, 2010.
3. Lin, G.-Q.; Li, Y.-M.; Chan, A.S.C. *Principles and Applications of Asymmetric Synthesis*; Wiley & Sons: New York, NY, USA, 2001.
4. Yoon, T.P.; Jacobsen, E.N. Privileged Chiral Catalysts. *Science* **2003**, *299*, 1691–1693. [[CrossRef](#)] [[PubMed](#)]
5. Togni, A.; Breutel, C.; Schnyder, A.; Spindler, F.; Landert, H.; Tijani, A. A Novel Easily Accessible Chiral Ferrocenyldiphosphine for Highly Enantioselective Hydrogenation, Allylic Alkylation, and Hydroboration Reactions. *J. Am. Chem. Soc.* **1994**, *116*, 4062–4066. [[CrossRef](#)]
6. Tang, W.; Zhang, X. New Chiral Phosphorus Ligands for Enantioselective Hydrogenation. *Chem. Rev.* **2003**, *103*, 3029–3070. [[CrossRef](#)] [[PubMed](#)]
7. Blaser, H. The Chiral Switch of (S)-Metolachlor: A Personal Account of an Industrial Odyssey in Asymmetric Catalysis. *Adv. Synth. Catal.* **2002**, *344*, 17–31. [[CrossRef](#)]
8. Knochel, P.; Polborn, K.; Lotz, M. New Ferrocenyl Ligands with Broad Applications in Asymmetric Catalysis. *Angew. Chem. Int. Ed.* **2002**, *41*, 4708–4711. [[CrossRef](#)]
9. Cunningham, L.; Benson, A.; Guiry, P.J. Recent developments in the synthesis and applications of chiral ferrocene ligands and organocatalysts in asymmetric catalysis. *Org. Biomol. Chem.* **2020**, *18*, 9329–9370. [[CrossRef](#)]
10. Farrell, A.; Goddard, R.; Guiry, P.J. The preparation of ferrocene-containing phosphinamine ligands possessing central and planar chirality and their application in palladium-catalysed asymmetric allylic alkylation. *J. Org. Chem.* **2002**, *67*, 4209–4217. [[CrossRef](#)]
11. Cahill, J.P.; Guiry, P.J. The Application of Pd-Complexes of *trans*-2,5-Dialkylpyrrolidinylbenzylidiphenyl phosphines to Enantioselective Allylic Alkylation. *Tetrahedron Asymmetry* **1998**, *9*, 4301–4306. [[CrossRef](#)]
12. Cahill, J.P.; Bohnen, F.; Goddard, R.; Krüger, C.; Guiry, P.J. The Preparation of *trans*-2,5-Dialkylpyrrolidinylbenzylidiphenylphosphines: New Phosphinamine Ligands for Asymmetric Catalysis. *Tetrahedron Asymmetry* **1998**, *9*, 3831–3839. [[CrossRef](#)]
13. Cahill, J.P.; Cunneen, D.; Guiry, P.J. *trans*-2,5-Dialkylpyrrolidinyl-containing Phosphinamines; Synthetic and Mechanistic Studies in Pd-Catalysed Asymmetric Allylic Alkylation. *Tetrahedron Asymmetry* **1999**, *10*, 4157–4173. [[CrossRef](#)]
14. Ahern, T.; Müller-Bunz, H.; Guiry, P.J. The Synthesis of N,O-Ferrocenyl Pyrrolidine-Containing Ligands And Their Application in Diethyl- and Diphenylzinc Addition to Aromatic Aldehydes. *J. Org. Chem.* **2006**, *71*, 7596–7602. [[CrossRef](#)] [[PubMed](#)]
15. Meaney, K.; Goddard, R.; Bronger, R.P.J.; Guiry, P.J. The preparation of ferrocene-containing phosphinamine ligands possessing central and planar chirality and their application in palladium-catalysed allylic substitution. *Tetrahedron* **2021**, *90*, 132088. [[CrossRef](#)]
16. Boaz, N.W.; Debenham, S.D.; MacKenzie, E.B.; Large, S.E. Phosphinoferrocenylaminophosphines as Novel and Practical Ligands for Asymmetric Catalysis. *Org. Lett.* **2002**, *4*, 2421–2424. [[CrossRef](#)] [[PubMed](#)]
17. Boaz, N.W.; MacKenzie, E.B.; Debenham, S.D.; Large, S.E.; Ponasik, J.A. Synthesis and Application of Phosphinoferrocenylaminophosphine Ligands for Asymmetric Catalysis. *J. Org. Chem.* **2005**, *70*, 1872–1880. [[CrossRef](#)]
18. Krabbe, S.W.; Hatcher, M.A.; Bowman, R.K.; Mitchell, M.B.; McClure, M.S.; Johnson, J.S. Copper-Catalyzed Asymmetric Hydrogenation of Aryl and Heteroaryl Ketones. *Org. Lett.* **2013**, *15*, 4560–4563. [[CrossRef](#)]

19. Deng, J.; Hu, X.-P.; Huang, J.-D.; Yu, S.-B.; Wang, D.-Y.; Duan, Z.-C.; Zheng, Z. Enantioselective Synthesis of  $\beta^2$ -Amino Acids via Rh-Catalyzed Asymmetric Hydrogenation with BoPhoz-Type Ligands: Important Influence of an N–H Proton in the Ligand on the Enantioselectivity. *J. Org. Chem.* **2008**, *73*, 2015–2017. [[CrossRef](#)]
20. Duan, Z.-C.; Hu, X.-P.; Zhang, C.; Zheng, Z. Enantioselective Rh-Catalyzed Hydrogenation of 3-Aryl-4-phosphonobutenoates with a *P*-Stereogenic BoPhoz-Type Ligand. *J. Org. Chem.* **2010**, *75*, 8319–8321. [[CrossRef](#)]
21. Pan, C.; Gu, Z.; Zhang, M.; Zhu, Z. Palladium-Catalyzed Enantioselective Synthesis of 2-Aryl Cyclohex-2-enone Atropisomers: Platform Molecules for the Divergent Synthesis of Axially Chiral Biaryl Compounds. *Angew. Chem. Int. Ed.* **2017**, *56*, 4777–4781. [[CrossRef](#)]
22. Hu, X.-P.; Zheng, Z. Unsymmetrical Hybrid Ferrocene-Based Phosphine-Phosphoramidites: A New Class of Practical Ligands for Rh-Catalyzed Asymmetric Hydrogenation. *Org. Lett.* **2004**, *6*, 3585–3588. [[CrossRef](#)]
23. Jia, X.; Li, X.; Lam, W.S.; Kok, S.H.L.; Xu, L.; Lu, G.; Yeung, C.-H.; Chan, A.S.C. The synthesis of new chiral phosphine-phosphinites, phosphine-phosphoramidite, and phosphine-phosphite ligands and their applications in asymmetric hydrogenation. *Tetrahedron Asymmetry* **2004**, *15*, 2273–2278. [[CrossRef](#)]
24. Hu, X.-P.; Zheng, Z. Practical Rh(I)-Catalyzed Asymmetric Hydrogenation of  $\beta$ -(Acylamino)acrylates Using a New Unsymmetrical Hybrid Ferrocenylphosphine–Phosphoramidite Ligand: Crucial Influence of an N–H Proton in the Ligand. *Org. Lett.* **2005**, *7*, 419–422. [[CrossRef](#)] [[PubMed](#)]
25. Garro-Helion, F.; Merzouk, A.; Guibe, F. Mild and Selective Palladium(0)-Catalyzed Deallylation of Allylic Amines. Allylamine and Diallylamine as Very Convenient Ammonia Equivalents for the Synthesis of Primary Amines. *J. Org. Chem.* **1993**, *58*, 6109–6113. [[CrossRef](#)]
26. Reetz, M.T.; Gosberg, A.; Goddard, R.; Kyung, S.-H. Diphosphonites as highly efficient ligands for enantioselective rhodium-catalyzed hydrogenation. *Chem. Commun.* **1998**, 2077–2078. [[CrossRef](#)]
27. Ouyang, G.; Xiang, J.; Li, Y.; He, Y.; Fan, Q. Cation-Triggered Switchable Asymmetric Catalysis with Chiral Aza-CrownPho. *Angew. Chem. Int. Ed.* **2015**, *54*, 4334–4337. [[CrossRef](#)] [[PubMed](#)]
28. Meetsma, A.; de Vries, J.G.; Giacomina, F.; de Vries, A.H.M.; Lefort, L.; Panella, L. High Enantioselectivity Is Induced by a Single Monodentate Phosphoramidite Ligand in Iridium-Catalyzed Asymmetric Hydrogenation. *Angew. Chem. Int. Ed.* **2007**, *46*, 1497–1500. [[CrossRef](#)]
29. Doskocz, M.; Malinowska, B.; Młynarz, P.; Lejczak, B.; Kafarski, P. Long range phosphorus–phosphorus coupling constants in bis(phosphorylhydroxymethyl)benzene derivatives. *Tetrahedron Lett.* **2010**, *51*, 3406–3411. [[CrossRef](#)]
30. Hierso, J.-C.; Fihri, A.; Ivanov, V.V.; Hanquet, B.; Piriou, N.; Donnadiou, B.; Rebière, B.; Amardeil, R.; Meunier, P. “Through-Space” Nuclear Spin–Spin  $J_{PP}$  Coupling in Tetraphosphine Ferrocenyl Derivatives: A  $^{31}\text{P}$  NMR and X-ray Structure Correlation Study for Coordination Complexes. *J. Am. Chem. Soc.* **2004**, *126*, 11077–11087. [[CrossRef](#)]
31. Dai, L.-X.; Tu, T.; You, S.-L.; Deng, W.-P.; Hou, X.-L. Asymmetric Catalysis with Chiral Ferrocene Ligands. *Acc. Chem. Res.* **2003**, *36*, 659–667. [[CrossRef](#)]
32. Vineyard, B.D.; Knowles, W.S.; Sabacky, M.J. Catalytic Asymmetric Hydrogenation. *J. Chem. Soc. Chem. Commun.* **1972**, 10–11. [[CrossRef](#)]
33. Vineyard, B.D.; Knowles, W.S.; Sabacky, M.J.; Bachman, G.L.; Weinkauff, D.J. Asymmetric Hydrogenation. Rhodium Chiral Bisphosphine Catalyst. *J. Am. Chem. Soc.* **1977**, *99*, 5946. [[CrossRef](#)]
34. Kagan, H.; Dang, T.-P. Asymmetric Catalytic Reduction with Transition Metal Complexes. I. A Catalytic System of Rh (I) with (–)-2,3-O–Isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane, a New Chiral Diphosphine. *J. Am. Chem. Soc.* **1972**, *94*, 6429. [[CrossRef](#)]
35. Burk, M.J.  $\text{C}_2$ -Symmetric Bis(phospholanes) and Their Use in Highly Enantioselective Hydrogenation Reactions. *J. Am. Chem. Soc.* **1991**, *113*, 8518. [[CrossRef](#)]
36. Burk, M.J.; Wang, Y.M.; Lee, J.R. A Convenient Asymmetric Synthesis of  $\alpha$ -1-Arylalkylamines Through the Enantioselective Hydrogenation of Enamides. *J. Am. Chem. Soc.* **1996**, *118*, 5142. [[CrossRef](#)]
37. Mohara, B.; Stephan, M. Practical Enantioselective Hydrogenation of  $\alpha$ -Aryl- and  $\alpha$ -Carboxyamidoethylenes by Rhodium(I)-{1,2-Bis[*o*-*tert*-butoxyphenyl](phenyl)phosphino}ethane}. *Adv. Synth. Catal.* **2013**, *355*, 594–600. [[CrossRef](#)]
38. Li, X.; You, C.; Li, S.; Lv, H.; Zhang, Z. Nickel-Catalyzed Enantioselective Hydrogenation of  $\beta$ -(Acylamino) acrylates: Synthesis of Chiral  $\beta$ -Amino Acid Derivatives. *J. Org. Chem.* **2004**, *69*, 8157–8160. [[CrossRef](#)]
39. Tang, W.; Capacci, A.G.; White, A.; Ma, S.; Rodriguez, S.; Qu, B.; Savoie, J.; Patel, N.D.; Wei, X.; Haddad, N.; et al. Novel and Efficient Chiral Bisphosphorus Ligands for Rhodium-Catalyzed Asymmetric Hydrogenation. *Org. Lett.* **2010**, *12*, 1104–1107. [[CrossRef](#)]
40. Kohara, T.; Hashimoto, Y.; Saigo, K. Design, synthesis, and optical resolution of a novel non-natural chiral auxiliary, 1-(2,5-dimethoxyphenyl)ethylamine. Application to diastereoselective alkylation of aldimines. *Tetrahedron* **1999**, *55*, 6453–6464. [[CrossRef](#)]